BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23819759)

  • 1. Inhibition of androgen induces autophagy in benign prostate epithelial cells.
    Li M; Yang X; Wang H; Xu E; Xi Z
    Int J Urol; 2014 Feb; 21(2):195-9. PubMed ID: 23819759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-ARI induces autophagy of prostate epithelial cells through suppressing IGF-1 expression in prostate fibroblasts.
    Yang BY; Jiang CY; Dai CY; Zhao RZ; Wang XJ; Zhu YP; Qian YX; Yin FL; Fu XY; Jing YF; Han BM; Xia SJ; Ruan Y
    Cell Prolif; 2019 May; 52(3):e12590. PubMed ID: 30883989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
    Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
    Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
    Maria McCrohan A; Morrissey C; O'Keane C; Mulligan N; Watson C; Smith J; Fitzpatrick JM; Watson RW
    Cancer; 2006 Jun; 106(12):2743-52. PubMed ID: 16703599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.
    Geller J
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
    Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
    J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs.
    Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B
    Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer.
    Hsieh JT; Chen SC; Yu HJ; Chang HC
    Prostate; 2011 Jul; 71(10):1115-21. PubMed ID: 21557276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for atrophy and apoptosis in the prostates of men given finasteride.
    Rittmaster RS; Norman RW; Thomas LN; Rowden G
    J Clin Endocrinol Metab; 1996 Feb; 81(2):814-9. PubMed ID: 8636309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.
    Bauman TM; Sehgal PD; Johnson KA; Pier T; Bruskewitz RC; Ricke WA; Huang W
    Prostate; 2014 Jun; 74(9):923-32. PubMed ID: 24789081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells.
    Huang HF; Murphy TF; Shu P; Barton AB; Barton BE
    Mol Cancer; 2005 Jan; 4(1):2. PubMed ID: 15647107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology.
    Justulin LA; Acquaro C; Carvalho RF; Silva MD; Felisbino SL
    Int J Androl; 2010 Jun; 33(3):489-99. PubMed ID: 19490185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
    Sutton MT; Yingling M; Vyas A; Atiemo H; Borkowski A; Jacobs SC; Kyprianou N
    Prostate; 2006 Aug; 66(11):1194-202. PubMed ID: 16652387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia.
    Bozec A; Ruffion A; Decaussin M; Andre J; Devonec M; Benahmed M; Mauduit C
    J Clin Endocrinol Metab; 2005 Jan; 90(1):17-25. PubMed ID: 15507514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2.
    Hong GL; Park SR; Jung DY; Karunasagara S; Lee KP; Koh EJ; Cho K; Park SS; Jung JY
    J Ethnopharmacol; 2020 Mar; 250():112446. PubMed ID: 31812646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
    Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
    J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium meta-arsenite induces reactive oxygen species-dependent apoptosis, necrosis, and autophagy in both androgen-sensitive and androgen-insensitive prostate cancer cells.
    Kim Y; Jeong IG; You D; Song SH; Suh N; Jang SW; Kim S; Hwang JJ; Kim CS
    Anticancer Drugs; 2014 Jan; 25(1):53-62. PubMed ID: 24100277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.